Protein C News and Research

RSS

Study finds GRK2 molecule promotes cell death after heart attack

A molecule known to be involved in progressive heart failure has now been shown to also lead to permanent damage after a heart attack, according to researchers at Thomas Jefferson University.

16 Sep 2010

K.U.Leuven enters license agreement with Pfizer to commercialize anti-HIV drugs

K.U.Leuven announced today that on July 29th, 2010 they entered into a license agreement with Pfizer. The license agreement grants Pfizer exclusive and sublicenseable worldwide rights to further develop and commercialise K.U.Leuven's compounds with a new mechanism of action for the potential treatment of individuals infected with HIV, the virus that causes AIDS.

16 Sep 2010

Scientists reveal techniques to extend organ transplant life

Experts from the Medical Research Council (MRC) Centre for Transplantation at King's College London, based at Guy's Hospital, have revealed exciting new scientific developments for people with an organ transplant, intended to help prevent rejection of the new organ and extend its life.

16 Sep 2010

Researchers develop ChIP Enrichment Analysis to identify drug targets, biomarkers

Researchers from Mount Sinai School of Medicine have developed a new computational method that will help streamline the analysis of gene expression experiments and provide scientists with a better mechanistic understanding of the differences between diseased and normal cells. The new database and software, called ChIP Enrichment Analysis (ChEA), will revolutionize how researchers identify drug targets and biomarkers.

16 Sep 2010

ABCB4 gene causes bad cholesterol to accumulate in blood: Research

Scientists at the Southwest Foundation for Biomedical Research (SFBR) in San Antonio have found a gene that causes high levels of bad cholesterol to accumulate in the blood as a result of a high-cholesterol diet.

16 Sep 2010

Molecule in cells predicts success of radiotherapy in individual bladder cancer patients

CANCER RESEARCH UK scientists have identified a molecule in cells which could predict the success of radiotherapy to treat individual bladder cancer patients, reveals research published in Cancer Research1 today (Wednesday).

15 Sep 2010

Phase II clinical trial shows GTx-758 reduces serum free testosterone

GTx, Inc. today announced that in a Phase II, open label, pharmacokinetic-pharmacodynamic clinical trial, GTx-758, an oral selective estrogen receptor alpha agonist being developed to treat advanced prostate cancer, suppressed serum total testosterone to castrate levels, increased serum SHBG (sex hormone binding globulin), and markedly reduced serum free testosterone in healthy male volunteers.

15 Sep 2010

COTI selected for Canadian life sciences partnering mission

Critical Outcome Technologies Inc. announced today that the Company was selected by the Consulate General of Canada and BIOTECanada to attend a life sciences partnering mission in Boston, MA. This initiative is being held in conjunction with the BioPharm America conference taking place September 15-17, 2010.

15 Sep 2010

Oxford Nanopore signs new agreement to strengthen University of Oxford collaboration

Oxford Nanopore Technologies Ltd is pleased to announce a new agreement to strengthen the Company's collaboration with the University of Oxford. The Company will fund research in the laboratories of Professor Hagan Bayley and will partner exclusively with the University to develop revolutionary products for molecular analysis from these new discoveries.

From Oxford Nanopore Technologies 15 Sep 2010

Norgen Biotek launches three novel kits for urine sampling

Norgen Biotek Corp, a privately held Canadian biotechnology company focusing principally on advancing a powerful proprietary technology for application in sample preparation for nucleic acid (DNA, RNA and microRNA) and protein purification, today announced the expansion of its basket of urine-based sample preparation products by launching 3 new urine concentration, preservation and isolation kits.

15 Sep 2010

PLX-PAD therapy improves quality of life in CLI patients

Pluristem Therapeutics Inc. today reported that data from clinical trials show the Company's placenta-derived cell therapy, PLX-PAD, is safe and improves quality of life as well as other efficacy measurements in patients with Critical Limb Ischemia (CLI), the end-stage of Peripheral Artery Disease (PAD).

15 Sep 2010

Researchers unveil watercress compound can block pathway for cancer development

The research, unveiled at a press conference today (14 September 2010), shows that the watercress compound is able to interfere with the function of a protein which plays a critical role in cancer development.

15 Sep 2010

Arizona State University receives grant to protect warfighters from infectious diseases

Scientists at the Biodesign Institute at Arizona State University have received a 2-year, $5.3 million grant from the Defense Advanced Research Projects Agency (DARPA) to protect warfighters in the event of exposure to infectious diseases during deployment.

15 Sep 2010

Pepscan, Tibotec sign Research and License Agreement

Pepscan Therapeutics, the Netherlands based biotechnology firm focusing on protein mimicry technology for the generation of novel therapeutics, today announced that it has signed a Research and License Agreement with Tibotec Pharmaceuticals, Ireland. Under the agreement Pepscan using its CLIPS technology will work with Tibotec to develop novel therapeutic peptides against an undisclosed target.

14 Sep 2010

Life Technologies finalizes cell line license agreement for recombinant protein production

Life Technologies Corporation today announced that it has finalized cell line license agreements with a number of companies to provide rights to Life Technologies' proprietary CHO (Chinese hamster ovary) cell lines for the production of recombinant proteins used as therapeutic agents and vaccines.

14 Sep 2010

Notch1 protein impacts childhood leukemia progression: Study

A protein crucial for the immune response appears to be a key player in the progression of a devastating form of childhood leukemia called T-cell acute lymphoblastic leukemia (T-ALL). Suppressing the activity of the protein kills the leukemic cells, the study shows, opening a potential avenue to new drugs that could prevent progression of the disease.

14 Sep 2010

U of A team on cusp of developing simple predictive test for preeclampsia

A team of researchers from the University of Alberta is on the cusp of developing a simple test to accurately predict which women will develop preeclampsia - a condition that affects 4 million women a year and can result in the deaths of both mothers and their babies.

14 Sep 2010

New approach reduces JAK2 activity by pharmacologically targeting HSP90 protein

Myeloproliferative neoplasms (MPN) comprise a family of blood cancers characterized by clonal expansion of a single blood cell type. Untreated, these cancers can progress to bone marrow failure and acute myeloid leukemia. Several groups have identified activating mutations in the JAK2 gene as associated with MPN; JAK2 inhibition has therefore emerged as approach to MPN therapy.

14 Sep 2010

Researchers identify body's control switch system to eliminate damaged cells

St. Jude Children's Research Hospital scientists discovered a new mechanism cells use to maximize production of a key protein following DNA damage and demonstrated the potential of small molecules to regulate the process and protect healthy tissue.

14 Sep 2010

Researchers identify novel molecular pathway of Parkinson’s disease

A new study led by researchers at Columbia University Medical Center has identified a novel molecular pathway underlying Parkinson's disease and points to existing drugs which may be able to slow progression of the disease.

14 Sep 2010